Ghosh, JoydeepKobayashi, MichihiroRamdas, BaskarChatterjee, AnindyaMa, PeilinMali, Raghuveer SinghCarlesso, NadiaLiu, YanPlas, David R.Chan, Rebecca J.Kapur, Reuben2016-12-192016-12-19Ghosh, J., Kobayashi, M., Ramdas, B., Chatterjee, A., Ma, P., Mali, R. S., … Kapur, R. (2016). S6K1 regulates hematopoietic stem cell self-renewal and leukemia maintenance. The Journal of Clinical Investigation, 126(7), 2621–2625. https://doi.org/10.1172/JCI845650021-9738 1558-8238https://hdl.handle.net/1805/11657Hyperactivation of the mTOR pathway impairs hematopoietic stem cell (HSC) functions and promotes leukemogenesis. mTORC1 and mTORC2 differentially control normal and leukemic stem cell functions. mTORC1 regulates p70 ribosomal protein S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E–binding (eIF4E-binding) protein 1 (4E-BP1), and mTORC2 modulates AKT activation. Given the extensive crosstalk that occurs between mTORC1 and mTORC2 signaling pathways, we assessed the role of the mTORC1 substrate S6K1 in the regulation of both normal HSC functions and in leukemogenesis driven by the mixed lineage leukemia (MLL) fusion oncogene MLL-AF9. We demonstrated that S6K1 deficiency impairs self-renewal of murine HSCs by reducing p21 expression. Loss of S6K1 also improved survival in mice transplanted with MLL-AF9–positive leukemic stem cells by modulating AKT anden-USPublisher's Policyhematopoietic stem cellleukemiaS6K1Article